BIIB Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 9.89% compared to Biogen's net margin of 19.72%. Biogen's return on equity of 9.11% beat Gilead Sciences's return on equity of 32.29%.

Biogen has a consensus price target of $172.25, signalling upside risk potential of 45.76%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 18.71%. Given that Biogen has higher upside potential than Gilead Sciences, analysts believe Biogen is more attractive than Gilead Sciences.

Biogen has a beta of 0.125, which suggesting that the stock is 87.479% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.2% to investors and pays a quarterly dividend of $0.79 per share. Biogen pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Biogen quarterly revenues are $2.4B, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Biogen's net income of $240.5M is lower than Gilead Sciences's net income of $1.3B. Notably, Biogen's price-to-earnings ratio is 11.67x while Gilead Sciences's PE ratio is 20.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.76x versus 4.25x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 9.89% compared to Biogen's net margin of 50.24%. Biogen's return on equity of 9.11% beat Johnson & Johnson's return on equity of 30.18%.

Biogen has a consensus price target of $172.25, signalling upside risk potential of 45.76%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 10.36%. Given that Biogen has higher upside potential than Johnson & Johnson, analysts believe Biogen is more attractive than Johnson & Johnson.

Biogen has a beta of 0.125, which suggesting that the stock is 87.479% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. Biogen pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.4B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Biogen's net income of $240.5M is lower than Johnson & Johnson's net income of $11B. Notably, Biogen's price-to-earnings ratio is 11.67x while Johnson & Johnson's PE ratio is 17.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.76x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 9.89% compared to Biogen's net margin of 21.68%. Biogen's return on equity of 9.11% beat Eli Lilly and's return on equity of 78.25%.

Biogen has a consensus price target of $172.25, signalling upside risk potential of 45.76%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Biogen has a beta of 0.125, which suggesting that the stock is 87.479% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Biogen pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.4B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Biogen's net income of $240.5M is lower than Eli Lilly and's net income of $2.8B. Notably, Biogen's price-to-earnings ratio is 11.67x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.76x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 9.89% compared to Biogen's net margin of -907.48%. Biogen's return on equity of 9.11% beat Moderna's return on equity of -29.23%.

Biogen has a consensus price target of $172.25, signalling upside risk potential of 45.76%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 93.66%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Biogen has a beta of 0.125, which suggesting that the stock is 87.479% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.4B, which are larger than Moderna quarterly revenues of $107M. Biogen's net income of $240.5M is higher than Moderna's net income of -$971M. Notably, Biogen's price-to-earnings ratio is 11.67x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.76x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.